Abstract Details

Title Obesity is associated with Optic Neuritis severity in Male patients with Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P4 - Poster Session 4 (5:30 PM-6:30 PM)

Poster/Presentation
Number 9-012

Objective To evaluate the determinants of acute optic neuritis (AON) severity and recovery in multiple sclerosis (MS).

Background Obesity is an important modifiable risk factor of MS; a deeper biological understanding of this association is needed.

Design/Methods We included 61 patients with clinically isolated syndrome (CIS) and MS who had a history of AON and were enrolled in the Comprehensive Longitudinal Investigation at the Brigham and Women’s Hospital (CLIMB). We recorded AON severity and recovery according to visual acuity outcomes recorded before, at, and, after the relapse. We measured the serum concentration of estradiol, leptin, testosterone, sex hormone-binding globulin, and vitamin D. Body mass index (BMI) was measured at the visit. We performed a linear regression to test the association between BMI and serum hormones and AON severity and recovery. We performed separate analyses in male and female patients. All analyses were adjusted for age and disease duration.

Results Male patients with moderate/severe AON had significantly higher BMI than male patients with mild AON (31.26 kg/m² vs 25.73 kg/m^2,p = 0.03). Males with moderate/severe AON had higher serum estradiol levels than males with mild AON (34.24 nmol/L vs 23.06 nmol/L, p=0.04). Male patients also showed a near-significant association between serum leptin and AON severity (moderate/severe AON: 12.29 ng/mL vs mild AON: 4.1 ng/mL, p = 0.06). These observations were not replicated in female patients. We failed to find any association between AON recovery and BMI, as well as between serum hormones and AON recovery.

Conclusions BMI, serum leptin, and serum estradiol were associated with AON severity in male patients but not in female patients.

Authors/Disclosures
Duong T. Chu, MD (Yale New Haven Hospital) PRESENTER	Dr. Chu has nothing to disclose.
Mattia Rosso, MD (Medical University of South Carolina)	Dr. Rosso has nothing to disclose.
Cindy Gonzalez (Brigham and Women'S Hospital)	No disclosure on file
	No disclosure on file
Brian C. Healy	The institution of Mr. Healy has received research support from Analysis Group. The institution of Mr. Healy has received research support from Bristol-Myers Squibb. The institution of Mr. Healy has received research support from Verily Life Sciences. The institution of Mr. Healy has received research support from Novartis. The institution of Mr. Healy has received research support from Merck Serono. The institution of Mr. Healy has received research support from Genzyme.
Howard L. Weiner, MD (Brigham and Women'S Hospital)	Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tiziana Life Sciences. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for vTv Therapeutics. Dr. Weiner has stock in vTv Therapeutics. The institution of Dr. Weiner has received research support from National Institute of Health. The institution of Dr. Weiner has received research support from National MS Society. The institution of Dr. Weiner has received research support from Genzyme Corp. The institution of Dr. Weiner has received research support from Genentech, Inc. . The institution of Dr. Weiner has received research support from Verily Life Sciences LLC. The institution of Dr. Weiner has received research support from EMD Serono, Inc..
Tanuja Chitnis, MD, F�鶹��ýӳ�� (Brigham and Women's Hospital)	Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Chitnis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche-Genentech. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave Biosciences. Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Chitnis has received research support from Novartis. The institution of Dr. Chitnis has received research support from Sanofi. The institution of Dr. Chitnis has received research support from Octave. The institution of Dr. Chitnis has received research support from Genentech-Roche. The institution of Dr. Chitnis has received research support from Tiziana Life Sciences. The institution of Dr. Chitnis has received research support from Bristol-Myers Squibb. The institution of Dr. Chitnis has received research support from Wesley Clover.

�鶹��ýӳ��

�鶹��ýӳ��